Actavis plc’s (ACT – Analyst Report) first quarter 2015 earnings came in at $4.30 per share, beating the Zacks Consensus Estimate of $3.84 per share by a huge margin and increasing 23.2% from the year-ago period.

Actavis Inc. – Earnings Surprise | FindTheCompany

Revenues for the reported quarter came in at $4.23 billion, up 59% from the year-ago period, beating the Zacks Consensus Estimate of $4.05 billion.

Reported quarter results included the impact of the Allergan acquisition, effective Mar 17.

Quarterly Details

Actavis has three revenue producing segments — North American Brands, North American Generics and International (generic, branded generic, brands outside North America and over-the-counter pharmaceutical products) and Anda Distribution.

North American Brands revenue soared to $1.74 billion (up significantly from $594 million in the year-ago period), driven by the Forest acquisition and the performance of legacy products like Lo Loestrin ($83.3 million), Minastrin 24 Fe ($65.4 million), and Estrace Cream ($71.9 million). Products like Bystolic ($164.1 million) and Linzess ($96.2 million) also performed well.

Actavis continues to convert patients to Namenda XR. The company said that about 49% patients have been converted.

CNS, gastroenterology, women’s health, cardiovascular, respiratory & acute care, urology, infectious disease and dermatology/established brands revenues came in at $541.6 million, $376.6 million, $267.5 million, $215.9 million, $68.3 million, $37.8 million and $228.3 million, respectively.

North American Generics revenues were $1.78 billion, up 6.4% from the year-ago period. Generic Concerta and Lidoderm performed well and results were boosted further by the new launches of generic versions of Intuniv and OxyContin.

International revenues declined 14% from the year-ago period to $558 million reflecting the divestiture of Western European assets in the second quarter of 2014 as well as the negative impact of currency movement.